US 11,746,335 B2
Development of dengue virus vaccine components
Stephen S. Whitehead, Bethesda, MD (US); Joseph E. Blaney, Gettysburg, PA (US); Brian R. Murphy, Bethesda, MD (US); and Ching-Juh Lai, Bethesda, MD (US)
Assigned to The Government of the United States of American, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The Government of the USA as represented by the Secretary, Dept. of Health and Human Services, Bethesda, MD (US)
Filed on Apr. 19, 2022, as Appl. No. 17/724,037.
Application 16/173,217 is a division of application No. 14/742,533, filed on Jun. 17, 2015, granted, now 10,160,957, issued on Dec. 25, 2018.
Application 13/692,557 is a division of application No. 12/376,756, granted, now 8,337,860, issued on Dec. 25, 2012, previously published as PCT/US2007/076004, filed on Aug. 15, 2007.
Application 17/724,037 is a continuation of application No. 16/912,359, filed on Jun. 25, 2020, granted, now 11,332,722.
Application 16/912,359 is a continuation of application No. 16/173,217, filed on Oct. 29, 2018, granted, now 10,724,007, issued on Jul. 28, 2020.
Application 14/742,533 is a continuation of application No. 13/692,557, filed on Dec. 3, 2012, granted, now 9,090,873, issued on Jul. 28, 2015.
Claims priority of provisional application 60/837,723, filed on Aug. 15, 2006.
Prior Publication US 2022/0251521 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 7/04 (2006.01); C12N 7/00 (2006.01); C07K 14/005 (2006.01); C07K 14/18 (2006.01); A61K 39/00 (2006.01)
CPC C12N 7/045 (2013.01) [C07K 14/005 (2013.01); C07K 14/1825 (2013.01); C12N 7/00 (2013.01); A61K 2039/5254 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24162 (2013.01); Y02A 50/30 (2018.01)] 4 Claims
 
1. A tetravalent immunogenic composition comprising nucleic acids encoding each of DEN1, DEN2, DEN3, and DEN4, wherein each nucleic acid has a Δ30/Δ31 mutation in the 3′-untranslated region (3′-UTR), wherein:
the mutation deletes nucleotides 174-145 and nucleotides 258-228 of DEN1;
the mutation deletes nucleotides 173-144 and nucleotides 258-228 of DEN2;
the mutation deletes nucleotides 173-143 and nucleotides 258-228 of DEN3; and
the mutation deletes nucleotides 172-143 and nucleotides 258-228 of DEN4, designated with the reverse order numbering system.